536 related articles for article (PubMed ID: 9773858)
1. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.
Date H; Lynch JP; Sundaresan S; Patterson GA; Trulock EP
J Heart Lung Transplant; 1998 Sep; 17(9):869-75. PubMed ID: 9773858
[TBL] [Abstract][Full Text] [Related]
2. Lung transplantation: a decade of experience.
Moffatt SD; Demers P; Robbins RC; Doyle R; Wienacker A; Henig N; Theodore J; Reitz BA; Whyte RI
J Heart Lung Transplant; 2005 Feb; 24(2):145-51. PubMed ID: 15701428
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients.
Dusmet M; Maurer J; Winton T; Kesten S
J Heart Lung Transplant; 1996 Sep; 15(9):948-54. PubMed ID: 8889991
[TBL] [Abstract][Full Text] [Related]
4. Are heart-lung transplant recipients protected from developing bronchiolitis obliterans syndrome?
Moffatt-Bruce SD; Karamichalis J; Robbins RC; Whyte RI; Theodore J; Reitz BA
Ann Thorac Surg; 2006 Jan; 81(1):286-91; discussion 291. PubMed ID: 16368382
[TBL] [Abstract][Full Text] [Related]
5. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
Heng D; Sharples LD; McNeil K; Stewart S; Wreghitt T; Wallwork J
J Heart Lung Transplant; 1998 Dec; 17(12):1255-63. PubMed ID: 9883768
[TBL] [Abstract][Full Text] [Related]
6. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
[TBL] [Abstract][Full Text] [Related]
7. Bronchiolitis obliterans syndrome development in lung transplantation patients.
Parada MT; Alba A; Sepúlveda C
Transplant Proc; 2010; 42(1):331-2. PubMed ID: 20172344
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: an important confounder?
Burton CM; Iversen M; Mortensen J; Carlsen J; Andersen CB; Milman N; Scheike T
J Heart Lung Transplant; 2007 Nov; 26(11):1127-34. PubMed ID: 18022078
[TBL] [Abstract][Full Text] [Related]
9. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection.
Sarahrudi K; Estenne M; Corris P; Niedermayer J; Knoop C; Glanville A; Chaparro C; Verleden G; Gerbase MW; Venuta F; Böttcher H; Aubert JD; Levvey B; Reichenspurner H; Auterith A; Klepetko W
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1126-32. PubMed ID: 15052212
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience.
Benden C; Speich R; Hofbauer GF; Irani S; Eich-Wanger C; Russi EW; Weder W; Boehler A
Transplantation; 2008 Dec; 86(11):1625-7. PubMed ID: 19077900
[TBL] [Abstract][Full Text] [Related]
11. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.
Valentine VG; Gupta MR; Walker JE; Seoane L; Bonvillain RW; Lombard GA; Weill D; Dhillon GS
J Heart Lung Transplant; 2009 Feb; 28(2):163-9. PubMed ID: 19201342
[TBL] [Abstract][Full Text] [Related]
12. Primary graft dysfunction and long-term pulmonary function after lung transplantation.
Whitson BA; Prekker ME; Herrington CS; Whelan TP; Radosevich DM; Hertz MI; Dahlberg PS
J Heart Lung Transplant; 2007 Oct; 26(10):1004-11. PubMed ID: 17919620
[TBL] [Abstract][Full Text] [Related]
13. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis.
Valentine VG; Robbins RC; Berry GJ; Patel HR; Reichenspurner H; Reitz BA; Theodore J
J Heart Lung Transplant; 1996 Apr; 15(4):371-83. PubMed ID: 8732596
[TBL] [Abstract][Full Text] [Related]
14. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome.
Borro JM; Bravo C; Solé A; Usetti P; Zurbano F; Lama R; De la Torre M; Román A; Pastor A; Laporta R; Cifrián JM; Santos F
Transplant Proc; 2007 Sep; 39(7):2416-9. PubMed ID: 17889206
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome.
Kesten S; Chaparro C; Scavuzzo M; Gutierrez C
J Heart Lung Transplant; 1997 Sep; 16(9):905-12. PubMed ID: 9322139
[TBL] [Abstract][Full Text] [Related]
16. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients.
Hohlfeld J; Niedermeyer J; Hamm H; Schäfers HJ; Wagner TO; Fabel H
J Heart Lung Transplant; 1996 Sep; 15(9):888-94. PubMed ID: 8889984
[TBL] [Abstract][Full Text] [Related]
17. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.
Burton CM; Iversen M; Carlsen J; Mortensen J; Andersen CB; Steinbrüchel D; Scheike T
J Heart Lung Transplant; 2009 Sep; 28(9):888-93. PubMed ID: 19716040
[TBL] [Abstract][Full Text] [Related]
18. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.
Westall GP; Michaelides A; Williams TJ; Snell GI; Kotsimbos TC
Transplantation; 2003 Jun; 75(12):2064-8. PubMed ID: 12829913
[TBL] [Abstract][Full Text] [Related]
19. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
[TBL] [Abstract][Full Text] [Related]
20. The killer immunoglobulin-like receptor (KIR) group A haplotype is associated with bronchiolitis obliterans syndrome after lung transplantation.
Kwakkel-van Erp JM; van de Graaf EA; Paantjens AW; van Ginkel WG; Schellekens J; van Kessel DA; van den Bosch JM; Otten HG
J Heart Lung Transplant; 2008 Sep; 27(9):995-1001. PubMed ID: 18765192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
